Exploring the Interplay between Cellular Senescence, Immunity, and Fibrosing Interstitial Lung Diseases: Challenges and Opportunities
- PMID: 39062798
- PMCID: PMC11276754
- DOI: 10.3390/ijms25147554
Exploring the Interplay between Cellular Senescence, Immunity, and Fibrosing Interstitial Lung Diseases: Challenges and Opportunities
Abstract
Fibrosing interstitial lung diseases (ILDs) are characterized by the gradual and irreversible accumulation of scar tissue in the lung parenchyma. The role of the immune response in the pathogenesis of pulmonary fibrosis remains unclear. In recent years, substantial advancements have been made in our comprehension of the pathobiology driving fibrosing ILDs, particularly concerning various age-related cellular disturbances and immune mechanisms believed to contribute to an inadequate response to stress and increased susceptibility to lung fibrosis. Emerging studies emphasize cellular senescence as a key mechanism implicated in the pathobiology of age-related diseases, including pulmonary fibrosis. Cellular senescence, marked by antagonistic pleiotropy, and the complex interplay with immunity, are pivotal in comprehending many aspects of lung fibrosis. Here, we review progress in novel concepts in cellular senescence, its association with the dysregulation of the immune response, and the evidence underlining its detrimental role in fibrosing ILDs.
Keywords: cellular senescence; immunosenescence; lung fibrosis.
Conflict of interest statement
F.H.-G. and J.S. report honoraria for lectures, educational events, and support for attending meetings from Roche, Boehringer Ingelheim, AstraZeneca, Gebro, and GSK, outside the submitted work. J.S. discloses consulting fees from Boehringer Ingelheim and Alofarma, and grants from Roche and Boehringer Ingelheim, all outside the submitted work. P.C. reports honoraria for lectures, educational events, and support for attending meetings from AstraZeneca, GSK, Sanofi and Chiesi, outside the submitted work. R.F. reports honoraria for lectures and support for attending meetings from Chiesi and Zambon; grants from GSK, AstraZeneca, and Menarini; and consulting fees from GSK, all outside the submitted work. M.S. is shareholder of Altos Labs, Inc., Senolytic Therapeutics, Inc., Life Biosciences, Inc., and Rejuveron Senescence Therapeutics, AG. J.A.G-P. reports honoraria for lectures, educational events, and support for attending meetings from AbbVie, AstraZeneca, Boehringer Ingelheim, GSK, Galapagos, Janssen, Lilly, and Otsuka, outside the submitted work. The funders had no role in the writing of the manuscript. The remaining authors declare no conflicts of interest.
Figures
References
-
- Travis W.D., Costabel U., Hansell D.M., King T.E., Jr., Lynch D.A., Nicholson A.G., Ryerson C.J., Ryu J.H., Selman M., Wells A.U., et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013;188:733–748. doi: 10.1164/rccm.201308-1483ST. - DOI - PMC - PubMed
-
- Raghu G., Remy-Jardin M., Richeldi L., Thomson C.C., Inoue Y., Johkoh T., Kreuter M., Lynch D.A., Maher T.M., Martinez F.J., et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2022;205:e18–e47. doi: 10.1164/rccm.202202-0399ST. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
- FEDER Funds (FIS17/00369, FIS19/01152)/Instituto de Salud Carlos III
- Beca SEPAR 2022, Beca SEPAR 2023/Sociedad Española de Neumología y Cirugía Torácica
- Beca SOCAP 2021/Societat Catalana de Pneumologia
- PFIS predoctoral scholarship (FI19/00054)/Instituto de Salud Carlos III
- ID 100010434, LCF/BQ/PI22/11910042/La Caixa Young Leadership Fellow
LinkOut - more resources
Full Text Sources
Medical
